Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomatitis 9Neoplasms 6Head and Neck Neoplasms 4Multiple Myeloma 2Mucositis 2Leukemia 2Xerostomia 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Oral Ulcer 1Lymphoma, Non-Hodgkin 1Lymphoma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Laryngeal Diseases 1Hematologic Neoplasms 1Graft vs Host Disease 1Deglutition Disorders 1Colonic Neoplasms 1Cataract 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Bevacizumab 27Leucovorin 23Fluorouracil 22Oxaliplatin 17Irinotecan 15Cetuximab 14pembrolizumab 11IFL protocol 11Panitumumab 10Folfox protocol 10Capecitabine 10Gemcitabine 7adagrasib 5Cisplatin 5Carboplatin 5Ramucirumab 4Colonoscopy 4veliparib 3spartalizumab 3selpercatinib 3regorafenib 3labetuzumab 3durvalumab 3conatumumab 3cemiplimab 3Pemetrexed 3Paclitaxel 3HMPL-013 3Drug Therapy 35,11-methenyltetrahydrohomofolate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Colonic Neoplasms × Fibroblast Growth Factor 7 × Clear all
NCT00393822 2014-07-15

A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Stage 2B or 3 Locally Advanced, Colon Cancer

Amgen

Phase 2/3 Completed
100 enrolled
Gastrointestinal

Colonic Neoplasms, Neoplasms, Stomatitis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡